June 16th, 2025 | 07:00 CEST
Novo Nordisk, dynaCERT, Verbio – Do not panic!
No, Donald Trump was not the focus of attention this week, even though the US president invited people to a parade to celebrate his 79th birthday. Instead, the escalating conflict between Iran and Israel dominated the last few days of the trading week. So far, investors seem relatively unimpressed by the flaring conflict. Energy stocks, especially oil producers, have risen sharply, which could signal an end to the correction of the past few months.
time to read: 3 minutes
|
Author:
Stefan Feulner
ISIN:
NOVO NORDISK A/S | DK0062498333 , DYNACERT INC. | CA26780A1084 , VERBIO VER.BIOENERGIE ON | DE000A0JL9W6
Table of contents:
"[...] The VERRA certification adds credibility to dynaCERT's emission reduction technologies by demonstrating compliance with internationally recognized standards for carbon emissions reductions and sustainable development. [...]" Jim Payne, CEO, dynaCERT Inc.
Author
Stefan Feulner
The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.
Tag cloud
Shares cloud
Novo Nordisk – Continuing upward
While the Danes were the celebrated stock market stars last year, becoming the most valuable company in Europe, the euphoria has evaporated dramatically in recent months. Between June 2024 and April 2025, Novo shares fell by a whopping 62% to an interim low of USD 57. Since then, the price has rebounded, currently standing at USD 79.83. The 200 EMA is around USD 83, and the downward trend that has formed since the all-time high is also in this range. A sustained break could take the share price to the horizontal resistance level at USD 112.52.
Novo Nordisk has recently made two significant announcements. Firstly, after consultation with regulatory authorities, the Company announced that it would be moving its experimental weight loss drug Amycretin into late-stage development.
Second, NVIDIA CEO Jensen Huang announced earlier this week in Paris that Novo and the US tech giant will be working together. The partnership is related to the agreement between Novo Nordisk and the Danish Center for AI Innovation (DCAI) to use "Gefion", Denmark's national AI supercomputer. The AI specialist announced this on Wednesday at the VivaTech conference in Paris.
The collaboration will focus on developing customized AI models and AI agents to support Novo Nordisk in both early drug discovery and clinical development. In addition, there are plans to use advanced simulations and physics-based AI technologies.
dynaCERT – Expansion in sight
The hydrogen specialist's share price has been trading sideways in the CAD 0.15 range for months. However, a lot is going on behind the scenes that will likely lead to stronger movements soon. The Company, valued at CAD 71.32 million, has been listed on the OTCQB Venture Market in the US since June, which should lead to an early increase in liquidity for the stock.
From a fundamental perspective, the signs continue to point to expansion. With its patented HydraGEN™ product line, developed over many years, dynaCERT has built up an effective tool for increasing the efficiency of combustion engines. Depending on the area of application, HydraGEN™ enables fuel savings of between 5% and 19%, which is a clear advantage for buyers in times of high energy prices and growing sustainability requirements. In addition, dynaCERT's HydraLytica™ analysis software enables the documentation of emissions savings, for example, of CO2 and nitrogen oxides, which can be used to generate tradable emission credits.
Following the successful "bauma 2025" trade fair, pre-production of 1,000 units was started to meet the expected demand from transport companies, logistics providers, and construction equipment operators. With rising energy prices, experts expect oil prices to remain well above USD 100 despite the current correction, which should lead to stronger demand for HydraGEN™. With an investment of USD 6,000 per unit, the payback period is less than a year in some cases.
Verbio – Trump gives hope
Biofuel producer Verbio bucked the trend in the past trading week. With a gain of around 13% to EUR 10.91, the SDAX stock ranks at the top of the leaderboards. If the horizontal resistance level at EUR 11.35 is broken, Verbio shares are likely to make another attempt at their previous high for the year of EUR 13.03.
After the quarterly figures were announced, the research firm Jefferies reiterated its rating of "Hold" and a price target of EUR 10.50. The Zörbig-based company thus fell slightly short of expectations due to lower profitability in the biodiesel business.
Nevertheless, thanks to Donald Trump, Verbio offers considerable potential. The old and new president of the United States plans to increase the promotion of biofuels. The new regulations presented by the US Environmental Protection Agency (EPA) provide for an increase in the blending quota for biofuels to 24.02 billion gallons. This represents an increase of just under 8% over the previous year and marks a new record. Conventional fuels such as gasoline and diesel will be affected, with larger quantities of biofuels such as ethanol or biodiesel to be added in the future. At the same time, the EPA plans to restrict the use of imported biofuel components.
Verbio already operates a production plant in the US state of Iowa, in the city of Nevada. Verbio also plans to expand its production capacities in the United States. The Company is also active in Canada, where it produces biodiesel.
Biofuel producer Verbio could benefit from increased subsidies in the US. Novo Nordisk announced two promising developments. dynaCERT increased pre-production of its devices due to high demand.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
